Results from a phase Ib study of trastuzumab emtansine (T-DM1), paclitaxel (T), and pertuzumab (P) in patients with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab.

被引：0
|
作者：
Modi, Shanu
Elias, Anthony D.
LoRusso, Patricia
Samant, Meghna
Guardino, Ellie
Althaus, Betsy
Krop, Ian E.
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Univ Colorado, Ctr Canc, Aurora, CO USA
[3] Karmanos Canc Inst, Detroit, MI USA
[4] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland
[5] Genentech Inc, San Francisco, CA 94080 USA
[6] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
528
引用
收藏
页数：1
相关论文
共 50 条
  • [21] PHASE I STUDY OF TRASTUZUMAB EMTANSINE (T-DM1) IN HER2-POSITIVE METASTATIC BREAST CANCER (MBC) PATIENTS WITH NORMAL OR REDUCED HEPATIC FUNCTION.
    Agarwal, P.
    Li, C.
    Gibiansky, L.
    Dent, S.
    Goncalves, A.
    Nijem, I.
    Strasak, A.
    Lorusso, P.
    Girish, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S21 - S21
  • [22] Efficacy of T-DM1 in patients with HER2-positive metastatic breast cancer previously treated with pertuzumab
    Matsui, K.
    Yoshikawa, A.
    Oyama, K.
    Nozaki, Z.
    Tanada, Y.
    Earashi, M.
    Kiyohara, K.
    Nagata, T.
    Fukushima, W.
    Shimizu, T.
    Maeda, K.
    ANNALS OF ONCOLOGY, 2017, 28
  • [23] Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy
    Sarika Jain
    Ami N. Shah
    Cesar A. Santa-Maria
    Kalliopi Siziopikou
    Alfred Rademaker
    Irene Helenowski
    Massimo Cristofanilli
    William J. Gradishar
    Breast Cancer Research and Treatment, 2018, 171 : 371 - 381
  • [24] Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy
    Jain, Sarika
    Shah, Ami N.
    Santa-Maria, Cesar A.
    Siziopikou, Kalliopi
    Rademaker, Alfred
    Helenowski, Irene
    Cristofanilli, Massimo
    Gradishar, William J.
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 171 (02) : 371 - 381
  • [25] Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane.
    Pegram, Mark D.
    Blackwell, Kimberly
    Miles, David
    Bianchi, Giulia Valeria
    Krop, Ian E.
    Welslau, Manfred
    Baselga, Jose
    Oh, Do-Youn
    Dieras, Veronique
    Guardino, Ellie
    Olsen, Steven R.
    Fang, Liang
    Lu, Michael
    Verma, Sunil
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (27)
  • [26] Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane.
    Blackwell, Kimberly L.
    Miles, David
    Gianni, Luca
    Krop, Ian E.
    Welslau, Manfred
    Baselga, Jose
    Pegram, Mark D.
    Do-Youn Oh
    Dieras, Veronique
    Olsen, Steven R.
    Fang, Liang
    Lu, Michael W.
    Guardino, Ellie
    Verma, Sunil
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [27] Trastuzumab emtansine plus pertuzumab in Japanese patients with HER2-positive metastatic breast cancer: a phase Ib study
    Noguchi, Emi
    Tamura, Kenji
    Hattori, Masaya
    Horiguchi, Jun
    Sato, Nobuaki
    Kanatani, Kazumitsu
    Matsunaga, Kiyoshi
    Iwata, Hiroji
    Fujiwara, Yasuhiro
    BREAST CANCER, 2019, 26 (01) : 39 - 46
  • [28] Trastuzumab emtansine plus pertuzumab in Japanese patients with HER2-positive metastatic breast cancer: a phase Ib study
    Emi Noguchi
    Kenji Tamura
    Masaya Hattori
    Jun Horiguchi
    Nobuaki Sato
    Kazumitsu Kanatani
    Kiyoshi Matsunaga
    Hiroji Iwata
    Yasuhiro Fujiwara
    Breast Cancer, 2019, 26 : 39 - 46
  • [29] Exposure-safety relationship of trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer (MBC)
    Jin, Jin
    Wang, Bei
    Gao, Yuying
    Samant, Meghan
    Li, Chunze
    Song, Chunyan
    Swain, Sandra M.
    Untch, Michael
    Girish, Sandhya
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [30] Adverse Events of Trastuzumab Emtansine (T-DM1) in the Treatment of HER2-Positive Breast Cancer Patients
    Kowalczyk, Lidia
    Bartsch, Rupert
    Singer, Christian F.
    Farr, Alex
    BREAST CARE, 2017, 12 (06) : 401 - 408
12345